Wassim Fares Net Worth

The estimated Net Worth of Wassim Fares is at least $160 dollars as of 10 September 2020. Wassim Fares owns over 4,000 units of Bellerophon Therapeutics Inc stock worth over $160 and over the last 4 years he sold BLPH stock worth over $0. In addition, he makes $0 as Chief Medical Officer. at Bellerophon Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Wassim Fares BLPH stock SEC Form 4 insiders trading

Wassim has made over 1 trades of the Bellerophon Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 4,000 units of BLPH stock worth $40,720 on 10 September 2020.

The largest trade he's ever made was buying 4,000 units of Bellerophon Therapeutics Inc stock on 10 September 2020 worth over $40,720. On average, Wassim trades about 2,000 units every 0 days since 2020. As of 10 September 2020 he still owns at least 4,000 units of Bellerophon Therapeutics Inc stock.

You can see the complete history of Wassim Fares stock trades at the bottom of the page.

Wassim Fares biography

Dr. Wassim Fares M.D. serves as Chief Medical Officer. of the Company. Dr. Fares is a board-certified pulmonologist and intensive care specialist with over 20 years of experience as a physician, principal investigator, associate professor, and pharmaceutical industry executive. Most recently, Dr. Fares was Senior Medical Director at Janssen Pharmaceutical Company and a member of Janssen's Pulmonary Hypertension therapeutic area development leadership team where he led developments across a broad range of potential indications, including fostering the design and execution of multiple Phase 1 through Phase 3 pivotal registration trials. Prior to Janssen, he consulted on clinical trial strategy for Actelion (Janssen/J&J), Bayer, Gilead, and United Therapeutics. Previously, Dr. Fares served in increasingly senior roles at Yale University, most recently as Director, a nationally-accredited Pulmonary Vascular Disease Center. Dr. Fares completed his post-graduate fellowship program in Pulmonary Disease and Critical Care Medicine at the University of North Carolina and his residency in Internal Medicine at St. Vincent Charity Medical Center. He earned medical and undergraduate degrees from the American University of Beirut, and a master's degree in clinical research from the University of North Carolina.

What's Wassim Fares's mailing address?

Wassim's mailing address filed with the SEC is 184 LIBERTY CORNER RD., SUITE 302, WARREN, NJ, 07059.

Insiders trading at Bellerophon Therapeutics Inc

Over the last 10 years, insiders at Bellerophon Therapeutics Inc have traded over $8,853,497 worth of Bellerophon Therapeutics Inc stock and bought 9,412,012 units worth $57,370,250 . The most active insiders traders include Robert Nelsen, Adam Weinstein, and Associates Iv L P Venrock H.... On average, Bellerophon Therapeutics Inc executives and independent directors trade stock every 61 days with the average trade being worth of $10,679. The most recent stock trade was executed by Capital Management Lp Puiss... on 13 October 2023, trading 1,076,841 units of BLPH stock currently worth $107,684.

What does Bellerophon Therapeutics Inc do?

bellerophon therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.

Complete history of Wassim Fares stock trades at Bellerophon Therapeutics Inc

Bellerophon Therapeutics Inc executives and stock owners

Bellerophon Therapeutics Inc executives and other stock owners filed with the SEC include:

• Fabian Tenenbaum,
  Chief Executive Officer, Chief Financial Officer, Chief Business Officer, Director
• Peter Fernandes,
  Chief Regulatory and Safety Officer
• Assaf Korner,
  Chief Financial Officer, Secretary
• Peter Fernandes M. Pharm,
  Interim Principal Exec. Officer, Chief Regulatory & Safety Officer
• Martin Dekker,
  Vice President - Engineering and Manufacturing
• Jonathan Peacock,
  Chairman of the Board
• Crispin Teufel,
  Independent Director
• Mary Cloyd,
  Independent Director
• Naseem Amin,
  Independent Director
• Andre Moura,
  Independent Director
• Theodore Wang,
  Independent Director
• Scott Bruder,
  Independent Director
• Matthew Bennett,
  Independent Director
• Wassim Fares,
  Chief Medical Officer.
• Amy Edmonds,
  Vice President - Clinical Operations and Administration
• Parag Shah,
  Vice President - Business Operations
• Dr. Edwin L. Parsley,
  Acting Chief Medical Officer
• Dr. Parag Suresh Shah,
  VP of Bus. Operations
• Nicholas Laccona,
  Principal Financial & Accounting Officer and Sec.
• Cross Border Opportunities ...,
  
• Megan Schoeps,
  Principal Financial Officer
• Matthew S. Holt,
  Director
• Deborah Quinn,
  Chief Medical Officer
• Adam Weinstein,
  Director
• Daniel Tasse,
  Director
• Mountain Investments Ii, Ll...,
  
• Life Science Opportunities ...,
  
• Associates Iv L P Venrock M...,
  
• Associates Iv L P Venrock H...,
  
• Associates Iv L P Venrock P...,
  
• Associates Iv L P Shah Nimi...,
  
• Associates Iv L P Venrock P...,
  
• Associates Iv L P Venrock H...,
  
• Jens Luehring,
  Director
• Venture Fund Vi Lparch Vent...,
  
• Martin Meglasson,
  Chief Scientific Officer
• Mountain Investments Ii, Ll...,
  
• Manesh Naidu,
  Chief Business Officer
• Robert Nelsen,
  Director
• North America, Inc. Linde,
  10% owner
• Amit Agrawal,
  Chief Operating Officer
• David Abrams,
  Treasurer
• R Scott Huennekens,
  Director
• Reinilde Heyrman,
  Chief Clinical Dev. Officer
• Associates Iv L Pvenrock En...,
  
• Life Science Opportunities ...,
  
• Nicholas Laccona,
  FINANCIAL OFFICER, (PFO & PAO)
• Capital Management Lp Puiss...,
  
• Life Science Opportunities ...,
  
• Bobae Kim,
  VP Reg. Affairs & Quality